Abstract
Objective The aim of this study is to evaluate the differential impact of BMI and long-term intra-individual BMI variability on the risk of developing heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF)in overweight or obese patients.
Method The primary outcome was the time to incident HFrEF or HFpEF determined by International Classification of Disease codes (ICD-9 and ICD-10). BMI variability was assessed based on five-year BMI measurements using four metrics: the intra-individual standard deviation (SD), the coefficient of variation (CV), the variability independent of the mean (VIM), and the average successive variability (ASV). The subclassification of HF was based on the LVEF recorded within 90 days of the initial diagnosis. The hazard ratios (HRs) were estimated by multivariable-adjusted Cox proportional hazards regression models.
Results Among the 51,444 eligible patients, 1,871 developed HFpEF, and 1,018 developed HFrEF over a follow-up period of the mean of 4.62 years. Per each 1-SD increment, the HRs of SD, CV, VIM and ASV of BMI were 1.10 (95%CI, 1.04-1.16), 1.04 (95%CI, 1.02-1.06), 1.16 (95%CI, 1.06-1.27) and 1.13 (95%CI, 1.04-1.22) for HFpEF, and 1.09 (95%CI, 1.00-1.18), 1.03 (95%CI, 1.00-1.06), 1.15 (95% CI, 1.02-1.31), and 1.08 (95%CI, 0.96-1.21), for HFrEF, respectively. Five statistical models were performed adjusting for different sets of covariates. Moreover, baseline BMI from patients in obesity II and III all exhibited progressively higher HRs for HFpEF with HRs of 1.45 (95%CI, 1.15-1.83), and 2.52 (95%CI, 1.99-3.19), while only patients in obesity class III demonstrated an increased risk for HFrEF with HR of 1.50 (95%CI, 1.11-2.04).
Conclusions and Relevance In this large cohort of overweight and obese patients, increasing BMI variability was associated with a higher risk of developing HFpEF and HFrEF after adjusting for relevant risk factors.
Study Importance What is already known:
The variability of body mass index (BMI) is a risk factor for negative cardiovascular outcomes in various cohorts.
A previous study showed that variability in adiposity indices is related to an increased risk of overall heart failure (HF) in patients with type two diabetes.
What are the new findings in your manuscript:
ur analysis examined the differential association between intra-individual BMI variability derived and the increased incidence of two subtypes of (HF), heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), using real-world clinical patient data.
associations were statistically significant across three different metrics, including standard deviation, coefficient of variation, and the variability independent of the mean.
might your results change the direction of research or the focus of clinical practice?
is important for clinicians to minimize body weight fluctuation in patients with overweight and obesity to meet weight loss goals due to its potential to reduce the risk of HF, especially given the increasing global prevalence of HFpEF and limited therapeutical options for it.
study also provides evidence of the feasibility and reliability of using electronic medical data collected from various clinical settings to define indicators for clinical decision-making
Competing Interest Statement
It is important to acknowledge the potential conflict of interest among the contributors to this research. ZY, MZ, NF, and LW report receiving research funding from Eli Lilly and Company within the past 12 months. TPR, NCS, YC, and FS are employees of Eli Lilly and Company and own company stock while the research was being conducted
Funding Statement
Eli Lilly and Company
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of University of Pittsburgh name gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
